Skip to main navigation menu Skip to main content Skip to site footer

No. 1 (2025)

NEW MEDICINES

Use of Cariprazine in the Treatment of Depressive Disorders

https://doi.org/10.48612/psyph/dz85-hre2-5ara

Published 2025-03-30

  • R.F. Nasyrova
    • ,
  • A.Y. Kibirova
    • ,
  • A.V. Kidyaeva

R.F. Nasyrova
V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology of the Ministry of Heath of the Russian Federation; St. Petersburg State Psychiatric Hospital of St. Nicholas; Altai State Medical University

A.Y. Kibirova
St. Petersburg State Psychiatric Hospital of St. Nicholas; Saint Petersburg State Pediatric Medical University

A.V. Kidyaeva
V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology of the Ministry of Heath of the Russian Federation; St. Petersburg State Psychiatric Hospital of St. Nicholas

Abstract

Background. Depressive disorders are among the most common mental disorders and are the leading cause of disability worldwide, reducing quality of life and increasing the incidence of suicide attempts and all-cause mortality in the population. Research suggests that only one third of patients achieve remission when treated with antidepressants and normotimics. This explains the use of atypical antipsychotics in the treatment of depressive disorders.

Objective — to analyze current data on the efficacy of cariprazine for the treatment of depressive disorders.

Methods. A search for full-text articles published from 01.11.2019 to 01.11.2024 was conducted in PubMed, eLIBRARY.RU, Google Scholar databases.

Results. This review analyzes and summarizes the results of studies on the use of cariprazine in the treatment of major depressive disorder and depressive episodes in bipolar affective disorder. The results showed that cariprazine was significantly superior to placebo in the treatment of bipolar depression, including resistant depression, reduced anxiety and did not cause phase inversion. The addition of cariprazine to antidepressant therapy for major depressive disorder made it possible to achieve a clinical response and remission, including in treatment-resistant patients. A dose of 1.5 mg/day of cariprazine for the treatment of depressive disorders was more effective than a dose of 3 mg/day and higher.

Conclusion. Thus, cariprazine is an effective drug for the treatment of depressive disorders.

Keywords

cariprazine, pharmacodynamics, depression, bipolar affective disorder, major depressive disorder

PDF (Русский)

References

  1. Depressive Disorder // IHME. – URL: https://www.healthdata.org/research-analysis/diseases-injuries-risks/factsheets/2021-major-depressive-disorder-level-4-disease (accessed July 25, 2024).
  2. Bipolar Disorder // IHME. – URL: https://www.healthdata.org/research-analysis/diseases-injuries-risks/factsheets/2021-bipolar-disorder-level-3-disease July 25, 2024). (accessed
  3. Huang W., Hu W., Cai L., Zeng G., Fang W., Dai X. et al. Acetate supplementation produces antidepressant-like effect via enhanced histone acetylation // J Affect Disord. – 2021. – Vol. 281. – Pp. 51–60. – https://doi.org/10.1016/j.jad.2020.11.121
  4. Walker E.R., McGee R.E., Druss B.G. Mortality in mental disorders and global disease bur den implications: a systematic review and meta-analysis // JAMA Psychiatry. – 2015. – Vol. 72 (4). – Pp. 334–341. – https://doi.org/10.1001/jamapsychiatry.2014.2502
  5. Friedrich M.J. Depression is the leading cause of disability around the world // JAMA. – 2017. – Vol. 317 (15). – Art. 1517. – https://doi.org/10.1001/jama.2017.3826
  6. Davis K., Remenyi B., Draper A.D., Dos Santos J., Bayley N., Paratz E. et al. Rheumatic heart disease in Timor-Leste school students: An echocardiography-based prevalence study // Med J Aust. – 2018. – Vol. 208 (7). – Pp. 303–307. – https://doi.org/10.5694/mja17.00666
  7. Ribeiro J.D., Huang X., Fox K.R., Franklin J.C. Depression and hopelessness as risk factors for suicide ideation, attempts and death: Meta-analysis of longitudinal studies // Br J Psychiatry. – 2018. – Vol. 212 (5). – Pp. 279–286. – https://doi.org/10.1192/bjp.2018.27
  8. Bragdon L.B., Eng G.K., Recchia N., Collins K.A., Stern E.R. Cognitive neuroscience of obsessive-compulsive disorder // Psychiatr Clin North Am. – 2023. – Vol. 46 (1). – Pp. 53–67. – https://doi.org/10.1016/j.psc.2022.11.001
  9. Greenberg P.E., Fournier A.A., Sisitsky T., Pike C.T., Kessler R.C. The economic burden of adults with major depressive disorder in the United States (2005 and 2010) // J Clin Psychiatry. – 2015. – Vol. 76 (2). – Pp. 155–162. – https://doi.org/10.4088/JCP.14m09298
  10. Tondo L., Vаzquez G.H., Baldessarini R.J. Depression and mania in bipolar disorder // Curr Neuropharmacol. – 2017. – Vol. 15 (3). – Pp. 353–358. – https://doi.org/10.2174/1570159X14666160606210811
  11. Селиванов Г.Ю. Основы психиатрии. – СПб.: ФГБОУ ВО «Санкт-Петербургский университет ГПС МЧС России», 2023. – 216 с.
  12. Костюкова Е.Г. Расширение показаний антипсихотиков второго поколения: от шизофрении к биполярному аффективному расстройству // Современная терапия психических расстройств. – 2020. – № 3. – С. 29–37. – https://doi.org/10.21265/PSYPH.2020.79.73.004
  13. Baldessarini R.J., Vieta E., Calabrese J.R., Tohen M., Bowden C.L. Bipolar depression: Over view and commentary // Harv Rev Psychiatry. – 2010. – Vol. 18 (3). – Pp. 143–157. – https://doi.org/10.3109/10673221003747955
  14. Forte A., Baldessarini R.J., Tondo L., Vаzquez G.H., Pompili M., Girardi P. Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders // J Affect Disord. – 2015. – Vol. 178. – Pp. 71–78. – https://doi.org/10.1016/j.jad.2015.02.011
  15. Dome P., Rihmer Z., Gonda X. Suicide risk in bipolar disorder: A brief review // Medicina (Kaunas). – 2019. – Vol. 55 (8). – https://doi.org/10.3390/medicina55080403
  16. McIntyre R.S., Berk M., Brietzke E., Goldstein B.I., Lоpez-Jaramillo C., Kessing L.V., Mal hi G.S., Nierenberg A.A., Rosenblat J.D., Majeed A., Vieta E., Vinberg M., Young A.H., Man sur R.B. Bipolar disorders // Lancet. – 2020. – Vol. 396 (10265). – Pp. 1841–1856. – https://doi.org/10.1016/S0140-6736(20)31544-0
  17. Петрова Н.Н. Биполярное аффективное расстройство. Новые возможности терапии // Современная терапия психических расстройств. – 2022. – № 1. – С. 45–55. – https://doi.org/10.21265/PSYPH.2022.60.1.005
  18. Стрельцов Е.А. Применение атипичных антипсихотиков в терапии депрессивных эпизодов при биполярном расстройстве // медицинский вестник Юга России. – 2021. – Т. 12 (3). – С. 32–35. – https://doi.org/10.21886/2219-8075-2021-12-3-32-35
  19. Lоpez-Muñoz F., Shen W.W., D’Ocon P., Romero A., Álamo C. A History of the pharmacological treatment of bipolar disorder // Int J Mol Sci. – 2018. – Vol. 19 (7). – https://doi.org/10.3390/ijms19072143
  20. Meltzer H.Y., Gadaleta E. Contrasting typical and atypical antipsychotic drugs // Focus (Am Psychiatr Publ). – 2021. – Vol. 19 (1). – Pp. 3–13. – https://doi.org/10.1176/appi.focus.20200051
  21. Fava M. Diagnosis and definition of treatment-resistant depression // Biol Psychiatry. – 2003. – Vol. 53 (8). – Pp. 649–659. – https://doi.org/10.1016/s0006-3223(03)00231-2
  22. McIntyre R.S., Alsuwaidan M., Baune B.T., Berk M., Demyttenaere K., Goldberg J.F. et al. Treatment-resistant depression: Definition, prevalence, detection, management, and investigational interventions // World Psychiatry. – 2023. – Vol. 22 (3). – Pp. 394–412. – https://doi.org/10.1002/wps.21120
  23. Fava G.A., Cosci F., Guidi J., Rafanelli C. The deceptive manifestations of treatment resistance in depression: A new look at the problem // Psychother Psychosom. – 2020. – Vol. 89 (5). – Pp. 265–273. – https://doi.org/10.1159/000507227
  24. Jha M.K., Mathew S.J. Pharmacotherapies for treatment-resistant depression: How anti psychotics fit in the rapidly evolving therapeutic landscape // Am J Psychiatry. – 2023. – Vol. 180. – Pp. 190–199. – https://doi.org/10.1176/appi.ajp.20220543
  25. Мосолов С.Н., Костюкова Е.Г., Ушкалова А.В., Шафаренко А.А., Алфимов П.В. Алгоритмы биологической терапии биполярного аффективного расстройства // Современная терапия психических расстройств. – 2013. – № 4. – С. 31–39.
  26. Garnham J., Munro A., Slaney C., MacDougall M., Passmore M., Duffy A. et al. Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study // J Affect Disord. – 2007. – Vol. 104. – Pp. 185–190. – https://doi.org/10.1016/j.jad.2007.03.003
  27. Мосолов С.Н. Сравнительная эффективность профилактического применения карбона та лития, карбамазепина, вальпроата натрия при аффективных и шизоаффективных психозах // Журнал невропатологии и психиатрии имени С.С. Корсакова. – 1991. – № 4. – С. 78–83.
  28. Государственный регистр лекарственных средств. – URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=888732b8-f07d-4c3c-ab9c-e4e9c65b119e (дата об ращения 25.07.2024).
  29. Drugs@FDA: FDA-Approved Drugs. – Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204370 (accessed July 25, 2024).
  30. Hafizi S., Jones P.B., Stahl S.M., Dobler V., Galindo L., Griffiths G. et al., editors. Cambridge Prescriber’s Guide in Psychiatry. – Cambridge University Press, 2023. – https://doi.org/10.1017/9781108986335
  31. Pejuškoviс B., Munjiza Jovanoviс A., Pešiс D. Exploring cariprazine as a treatment option for varied depression symptom clusters // Front Psychiatry. – 2024. – Vol. 15. – Art. 1442699. – https://doi.org/10.3389/fpsyt.2024.1442699
  32. Насырова Р.Ф. Антипсихотик третьего поколения карипразин как перспективный препарат для терапии депрессивных расстройств // Современная терапия психических расстройств. – 2023. – № 2. – С. 21–29. – https://doi.org/10.21265/PSYPH.2023.86.41.003
  33. Yatham L.N., Vieta E., Earley W. Evaluation of cariprazine in the treatment of bipolar I and II depression: A randomized, double-blind, placebo-controlled, phase 2 trial // Int Clin Psychopharmacol. – 2020. – Vol. 35 (3). – Pp. 147–156. – https://doi.org/10.1097/YIC.0000000000000307
  34. Earley W.R., Burgess M.V., Khan B., Rekeda L., Suppes T., Tohen M. et al. Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study // Bipolar Disord. – 2020. – Vol. 22 (4). – Pp. 372–384. – https://doi.org/10.1111/bdi.12852
  35. Teobaldi E., Pessina E., Martini A., Cattaneo C.I., De Berardis D., Martiadis V. et al. Cariprazine augmentation in treatment-resistant bipolar depression: Data from a retrospective observational study // Curr Neuropharmacol. – 2024. – Vol. 22 (10). – Pp. 1742–1748. – https://doi.org/10.2174/1570159X22666240129095852
  36. Sachs G.S., Yeung P.P., Rekeda L., Khan A., Adams J.L., Fava M. Adjunctive cariprazine for the treatment of patients with major depressive disorder: A randomized, double-blind, placebo-controlled phase 3 study // Am J Psychiatry. – 2023. – Vol. 180 (3). – Pp. 241 251. – https://doi.org/10.1176/appi.ajp.20220504
  37. Papakostas G., Yeung P., Chen C., Waraich S., Kerolous M. Adjunctive cariprazine in patients with major depressive disorder: Post hoc analysis of efficacy by baseline antidepressant response // CNS Spectrums. – 2023. – Vol. 28. – Pp. 244–245.
  38. Patel M., Jain R., Tohen M., Maletic V., Earley W.R., Yatham L.N. Efficacy of cariprazine in bipolar I depression across patient characteristics: A post hoc analysis of pooled randomized, placebo-controlled studies // Int Clin Psychopharmacol. – 2021. – Vol. 36 (2). – Pp. 76–83. – https://doi.org/10.1097/YIC.0000000000000344
  39. Vieta E., McIntyre R.S., Yu J., Aronin L.C., Kramer K., Nguyen H.B. Full-spectrum efficacy of cariprazine across manic and depressive symptoms of bipolar I disorder in patients experiencing mood episodes: Post hoc analysis of pooled randomized controlled trial data // J Affect Disord. – 2024. – Vol. 366. – Pp. 136–145. – https://doi.org/10.1016/j.jad.2024.08.119
  40. McIntyre R.S., Suppes T., Earley W., Patel M., Stahl S.M. Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies // CNS Spectr. – 2020. – Vol. 25 (4). – Pp. 502–510. – https://doi.org/10.1017/S1092852919001287
  41. Jain R., McIntyre R.S., Cutler A.J., Earley W.R., Nguyen H.B., Adams J.L. et al. Efficacy of cariprazine in patients with bipolar depression and higher or lower levels of baseline anxiety: a pooled post hoc analysis // Int Clin Psychopharmacol. – 2024. – Vol. 39 (2). – Pp. 82–92. – https://doi.org/10.1097/YIC.0000000000000500
  42. Citrome L., Reda I., Kerolous M. Adjunctive cariprazine for the treatment of major depressive disorder: Number needed to treat, number needed to harm, and likelihood to be helped or harmed // J Affect Disord. – 2024. – https://doi.org/10.1016/j.jad.2024.10.040
  43. Ali E., Latif F., Mashkoor Y., Sheikh A., Iqbal A., Owais R. et al. Role of adjunctive cariprazine for treatment-resistant depression in patients with major depressive disorder: A systematic review and meta-analysis of randomized controlled trials // Asian J Psychiatr. – 2024. – Vol. 95. – Art. 104005. – https://doi.org/10.1016/j.ajp.2024.104005
  44. Martins-Correia J., Fernandes L.A., Kenny R., Salas B., Karmani S., Inskip A. et al. Cariprazine in the acute treatment of unipolar and bipolar depression: A systematic review and meta-analysis // J Affect Disord. – 2024. – Vol. 362. – Pp. 297–307. – https://doi.org/10.1016/j.jad.2024.06.099
  45. Gill H., Chen-Li D.C.J., Haikazian S., Seyedin S., McIntyre R.S., Mansur R.B. et al. Adjunctive cariprazine for major depressive disorder: A systematic review and meta-analysis // CNS Spectr. – 2024. – Vol. 29 (4). – Pp. 233–242. – https://doi.org/10.1017/S1092852924000178
  46. Li S., Xu C., Hu S., Lai J. Efficacy and tolerability of FDA-approved atypical antipsychotics for the treatment of bipolar depression: A systematic review and network meta-analysis // Eur Psychiatry. – 2024. – Vol. 67 (1). – e29. – https://doi.org/10.1192/j.eurpsy.2024.25
  47. Xie M., Qiu Y., Wang M., Wei X., Tao Y., Duan A. et al. Adjunctive cariprazine as a novel effective strategy for treating major depressive disorder: A systematic review and meta-analysis // J Psychiatr Res. – 2024. – Vol. 172. – Pp. 71–80. – https://doi.org/10.1016/j.jpsychires.2024.02.018
  48. Terao I., Kodama W. Comparative efficacy of dopamine partial agonists by doses for treat ment-resistant depression: A systematic review and dose-response model-based network meta-analysis // J Clin Psychopharmacol. – 2024. – Vol. 44 (4). – Pp. 413–417. – https://doi.org/10.1097/JCP.0000000000001862
  49. Tarchi L., Bugini S., Dani C., Cassioli E., Rossi E., Lucarelli S. et al. Efficacy of cariprazine in the psychosis spectrum: A systematic review and network meta-analysis of randomised controlled trials in schizophrenia and bipolar disorder // CNS Drugs. – 2024. – https://doi.org/10.1007/s40263-024-01125-9
  50. Cai L., Chen G., Yang H., Bai Y. Efficacy and safety profiles of mood stabilizers and antipsychotics for bipolar depression: a systematic review // Int Clin Psychopharmacol. – 2023. – Vol. 38 (4). – Pp. 249–260. – https://doi.org/10.1097/YIC.0000000000000449
  51. Кидяева А.В., Насырова Р.Ф. Роль карипразина в профилактике и коррекции кардиометаболических нарушений антипсихотической фармакотерапии // Современная терапия психических расстройств. – 2024. – № 3. – С. 51–57. – https://doi.org/10.21265/PSYPH.2024.75.87.005
  52. Nuñez N.A., Joseph B., Pahwa M., Kumar R., Resendez M.G., Prokop L.J. et al. Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis // J Affect Disord. – 2022. – Vol. 302. – Pp. 385–400. – https://doi.org/10.1016/j.jad.2021.12.134
  53. Earley W.R., Guo H., Nеmeth G., Harsаnyi J., Thase M.E. Cariprazine augmentation to an tidepressant therapy in major depressive disorder: Results of a randomized, double-blind, placebo-controlled trial // Psychopharmacol Bull. – 2018. – Vol. 48 (4). – Pp. 62–80.
  54. Riesenberg R., Yeung P.P., Rekeda L., Sachs G.S., Kerolous M., Fava M. Cariprazine for the adjunctive treatment of major depressive disorder in patients with inadequate response to antidepressant therapy: Results of a randomized, double-blind, placebo-controlled study // J Clin Psychiatry. – 2023. – Vol. 84 (5). – https://doi.org/10.4088/JCP.22m14643
  55. Avilov A.Y., Kidyaeva A.V., Vaiman E.E. Predictive pharmacogenetic testing in psychiatry: Pros and cons // Personalized Psychiatry and Neurology. – 2024. – Vol. 4 (1). – Pp. 40 49. – https://doi.org/10.52667/2712-9179-2024-4-1-40-49
  56. Sychev D.A. “Multiomic” studies as a promising clinical pharmacological tool for personalization of socially significant diseases pharmacotherapy in Russia // Personalized Psychiatry and Neurology. – 2022. – Vol. 2 (2). – Pp. 1–2. – https://doi.org/10.52667/2712-9179-2022-2-2-1-2
  57. Boyko I.R., Shnayder N.A., Grechkina V.V., Savelieva O.E. Frequency of “poor transporter” phenotype among patients with mental disorders: Pilot study // Personalized Psychiatry and Neurology. – 2024. – Vol. 4 (3). – Pp. 37–44. – https://doi.org/10.52667/2712-9179-2024-4-3-37-44
  58. Khasanova A.K., Nasyrova R.F. Pharmacogenetic testing of cytochrome P450 system enzymes in the therapy of bipolar affective disorder // Personalized Psychiatry and Neuro logy. – 2022. – Vol. 2 (2). – Pp. 90–96. – https://doi.org/10.52667/2712-9179-2022-2-2-90-96

Downloads

Download data is not yet available.